During the last session, Dermata Therapeutics Inc (NASDAQ:DRMA)’s traded shares were 75.95 million, with the beta value of the company hitting 0.49. At the end of the trading day, the stock’s price was $1.42, reflecting an intraday gain of 5.19% or $0.07. The 52-week high for the DRMA share is $6.67, that puts it down -369.72 from that peak though still a striking 29.58% gain since the share price plummeted to a 52-week low of $1.00. The company’s market capitalization is $7.71M, and the average intraday trading volume over the past 10 days was 7.77 million shares, and the average trade volume was 341.05K shares over the past three months.
Dermata Therapeutics Inc (DRMA) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.00. DRMA has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Dermata Therapeutics Inc (NASDAQ:DRMA) trade information
Dermata Therapeutics Inc (DRMA) registered a 5.19% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.19% in intraday trading to $1.42, hitting a weekly high. The stock’s 5-day price performance is 20.34%, and it has moved by 19.33% in 30 days. Based on these gigs, the overall price performance for the year is -77.20%. The short interest in Dermata Therapeutics Inc (NASDAQ:DRMA) is 0.19 million shares and it means that shorts have 1.02 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 76.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, DRMA is trading at a discount of -322.54% off the target high and -322.54% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 43.22%. While earnings are projected to return 87.60% in 2025.
DRMA Dividends
Dermata Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-16. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Dermata Therapeutics Inc (NASDAQ:DRMA)’s Major holders
Dermata Therapeutics Inc insiders own 23.27% of total outstanding shares while institutional holders control 0.84%, with the float percentage being 1.09%.
